logo-loader
viewBiocept Inc

Biocept pursuing new strategy with a physician association using its liquid biopsy cancer tests

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy test provider has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. Nall says this is the first value-based delivery system partnership of its kind for Biocept. Nall also mentioned the company will soon be launching its cerebral spinal fluid liquid biopsy test.

Quick facts: Biocept Inc

Price: 0.5323 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $71.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Biocept reveals double-digit revenue jump and new Target Selector molecular...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive how the California-based company saw revenue jump by double-digits in its fiscal first quarter despite headwinds from the coronavirus pandemic. What's more, Nall says the developer of liquid biopsy tests has released a new Target...

1 week, 2 days ago

2 min read